◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksH › HIGH

Cantourage Group SE (HIGH) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Cantourage Group SE (HIGH) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Berlin, Germany. Its market capitalization is roughly €69 million. In the fiscal year ended 2023-12-31, HIGH reported €24M in revenue and (€4M) in net income.

Cantourage Group SE operates as a medical cannabis company in Europe and internationally. The company offers cannabis flowers, extracts, dronabinol, tetrahydrocannabinol, and cannabidiol products. It exports its products. The company distributes its products through pharmacies, wholesalers, and partners.

Interactive charts & full statements →

HIGH Revenue & Earnings History — Annual Income Statement

Income statement2023-12-312022-12-312021-12-31
Total Revenue€24M€1M€5M
Gross Profit€7M€2M
Operating Income (EBIT)(€4M)€0M(€1M)
Net Income(€4M)€0M(€1M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HIGH Free Cash Flow History

HIGH Balance Sheet History

Balance sheet2023-12-312022-12-312021-12-31
Total Assets€44M€45M€5M
Total Liabilities€4M€1M€1M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HIGH viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← HIGAll “H” companiesHIHO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.